CIRC (HKEX: 01763) has announced a significant milestone for its operations. The company's subsidiary, Chengdu CNNC High-Tech Isotope Co., Ltd., has successfully obtained an expanded radiation safety license for the second phase of its radionuclide research, development, and production base. This achievement marks the complete construction and full operational commencement of what is now the largest facility of its kind in Asia.
The new phase includes the formal launch of production lines for radionuclides such as Californium-252, Cesium-137, and Americium-241. This expansion enables the comprehensive fulfillment of diverse market needs. The first phase of the base had already secured its radiation safety license in August 2025.
With the addition of this second phase, the facility now boasts 14 distinct production lines. These lines are capable of manufacturing high-quality radionuclide products from over 70 different isotopes, including Carbon-14 and Krypton-85 sources. The facility's annual production capacity is projected to exceed 100,000 units.
This enhanced production scale is designed to meet the current demand for radionuclides across various critical sectors within the country. Key industries served include industrial applications, agriculture, medical technology, national defense, and aerospace.
The full-scale operation of this project signifies a major acceleration in technological advancement and the transition to new production capacities within the nation's sealed radionuclide sector. It solidifies the country's leading position in the research, development, and industrial application of radionuclides.
Furthermore, with this new production capacity coming online, the related products will not only cater to domestic requirements but also support an intensified effort to expand into international markets. The initiative aims to actively serve countries involved in the Belt and Road Initiative.
Comments